Newsfile Corp
26 Jul 2026, 21:17 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Regeneron's Phase III Fianlimab-Libtayo Study failed to reach statistical significance for its primary endpoint of improvement in progression-free survival. — The failure of a Phase III trial for a key drug candidate represents a significant loss of future revenue potential and a failure of a major R&D pipeline asset.
-0.80Regeneron is facing a federal securities class action lawsuit alleging it made false or misleading statements regarding the Fianlimab-Libtayo study's statistical assumptions and clinical differentiation. — Securities litigation creates additional financial liability and reputational risk, though it follows the primary negative news of the trial failure.
-0.40The company previously altered the Phase III study to expand the number of patients eligible for progression-free survival analysis before the final failure was announced. — Mid-study modifications can be viewed by markets as a sign of desperation or an attempt to 'rescue' a failing trial, undermining management's credibility.
-0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Which stocks this story touches
The company is facing a securities class action lawsuit following the failure of a Phase III clinical trial and allegations of misleading investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
